Vibrant Therapeutics
June 23, 2026
Theater 4
Type: Company Presentation
Focus Area:
Brain Health
Vibrant Therapeutics is a clinical stage company focused on neurological disease, oncology and immunology. We have recently secured additional $61M funding led by Pfizer Ventures.
We have developed a proprietary differentiated transcytosis-based BBB-shuttle technology for antibody- and RNA-based payloads.
We have 2 lead antibody-based assets for neurological disease, with outstanding NHP data demonstrating best-in-class brain PK and safety, whose IND filing is expected within the next 6-9 months.
We have also generated in-vivo data on siRNA brain delivery and subsequent substantial knock-down of the target mRNA in different brain regions after i.v. administration.
Company HQ City:
Cambridge
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2019
Lead Product in Development:
VIB305, dual targeting EGFR masked TCE
CEO
Larry Wang and Han Lee
Development Phase of Lead Product
Phase I
When you expect your next catalyst update?
H2 2026
What is your next catalyst (value inflection) update?
Neurological disease assets IND filing; VIB305 clinical data on safety, PK and early signs of efficacy
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}